CARCINOGENESIS AND NOVEL THERAPEUTICS IN ORAL CANCER

芝加哥地区的口腔癌研究历史悠久。 在 本申请，芝加哥大学和西北大学 正在结合实验室和临床科学的努力， 实验室科学家和临床研究者之间的互动， 产生新的治疗假设并进行转化研究 在口腔癌中。我们将寻求优化目前可用的治疗方法， 促进口腔癌患者的康复。 我们的长期 目标是确定早期诊断的新方法， 基于对分子机制的理解的成功治疗 这一疾病的潜在原因。我们将支持试点项目， 利用发展的新的临床实验室假设的产生 研究经费由补助金提供， 参与机构和提供教育和培训，在口头 癌症研究的基础和临床研究人员。校长 调查人员有着悠久的合作历史， 进行了口腔癌发生和癌症治疗的独立研究 和康复。在本申请中描述了四个项目 项目#1将研究口腔癌发生的潜在机制， 可以为未来的早期检测确定工具。 项目#2将研究 细胞凋亡在口腔癌发生中的作用项目#3将研究分子 化疗伴随放疗的药代动力学 提供更有效和毒性更小的治疗。项目#4将测量 器官功能和康复治疗的患者 意向性放化疗还包括三个试点项目， 将由两个机构提供的赠款和配对资金资助， 参与机构。这些活动将得到三个方面的支持。 丹行政核心、生物统计、数据管理和 临床核心，以及组织采购和实验室核心。 核心A是行政核心，将监测正在进行的项目， 成功和及时地执行科学任务， 内部和外部咨询委员会。 核心B，生物统计学 数据管理和临床核心将提供数据方面的专业知识 收集和分析。核心C，实验室核心将负责 适当收集、制备和分发人类 正在进行的项目所需的组织。

There is a long history of oral cancer research in the Chicago area. In this application, the University of Chicago and Northwestern University are combining their efforts in laboratory and clinical sciences to foster interactions between laboratory scientists and clinical investigators, to generate new treatment hypothesis and conduct translational research in oral cancer. We will seek to optimize currently available therapy and improve the rehabilitation of the oral cancer patient. Our long-term goals are to identify new approaches to early diagnosis and more successful therapy based on an understanding of the molecular mechanisms underlying this disease. We will support pilot projects and the rapid generation of new clinical laboratory hypotheses utilizing developmental research funds provided by the grant and supplemented by the participating institutions and provide education and training in oral cancer research for basic and clinical investigators. The principal investigators have a long history of collaboration and have also conducted independent studies of oral carcinogenesis and cancer therapy and rehabilitation. Four projects are described in this application Project #1 will examine mechanisms underlying oral carcinogenesis that may identify tools for future early detection. Project #2 will study the role of apoptosis in oral carcinogenesis. Project #3 will study molecular pharmacokinetics of chemotherapy with concomitant radiotherapy in order to deliver more effective and less toxic therapy. Project #4 will measure organ function and rehabilitation in patients treated with curative intent chemoradiotherapy. Three pilot projects are also included which will be funded by the grant and matching funds made available by the two participating institutions. These activities will be supported by three cores. The administrative core, the biostatistical, data management and clinical core, and the tissue procurement and laboratory core. Core A, the administrative core will monitor ongoing projects, assure successful and timely performance of scientific tasks and interact with the internal and external advisory boards. Core B, the biostatistical data management and clinical core will provide expertise in data collection and analysis. Core C, the laboratory core will be responsible for the appropriate collection, preparation and distribution of human tissues required for ongoing projects.